论文部分内容阅读
目的：了解ＩＮＦ－α２ｂ在多发性骨髓瘤中的应用价值。方法：对１５例住院的多发性骨髓瘤（ＭＭ）患者采用ＶＣＭＰ方案加ＩＮＦ－α２ｂ治疗（简称化疗＋干扰素组），与同期住院的３０例ＭＭ单纯化疗患者（简称纯化疗组）进行了临床观察。结果：显示化疗＋干扰素组完全缓解率（ＣＲ率）为７３．３％，总有效率为８６．６％；单纯化疗组ＣＲ率为４３．３％，总有效率为６０％。结论：ＩＮＦ－α２ｂ并化疗能明显提高患者的ＣＲ率，延长持续ＣＲ的时间，提高患者无病生存期，促进患者正常生活能力的恢复。
Objective: To understand the value of INF-α2b in multiple myeloma. Methods: 15 patients with multiple myeloma (MM) who were hospitalized were treated with VCMP plus INF-α2b (chemotherapy + interferon group), and 30 patients with MM chemotherapy (hospitalization for short) were hospitalized during the same period. Clinical Observation. Results: The complete remission rate (CR rate) in the chemotherapy + interferon group was 73.3%, the total effective rate was 86.6%; the CR rate in the chemotherapy alone group was 43.3%, and the total effective rate was 60%. Conclusion: INF-α2b plus chemotherapy can significantly increase the CR rate of patients, prolong the duration of continuous CR, improve the disease-free survival of patients, and promote the recovery of patients’ normal life ability.